$STX

MOSLEY WILLIAM D sold $1.6M of STX

MOSLEY WILLIAM D (CEO) sold 1,730 shares of Seagate Technology Holdings plc (STX) at $920.90 ($1.59M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MOSLEY WILLIAM D
Published Jun 2, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
high confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

Because the transaction is explicitly pre-arranged (10b5-1), it generally reduces the likelihood that the sale reflects new, time-sensitive negative information.

02

Market read

This is a routine insider disclosure; any trading impact is likely confined to short-term sentiment rather than fundamentals.

03

What to watch

The filing does not indicate sale intent beyond the plan; without context on prior sales cadence or total insider net activity, signal strength is limited.

Relevance 6/10Novelty 5/10Timing: Filed after-hours on 2026-06-02, covering a sale dated 2026-06-01.

Background

The article summarizes an SEC Form 4 insider transaction: CEO William D. Mosley sold 1,730 STX shares at ~$920.90 on 2026-06-01 under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$STXNeutralHigh confidence
Context

Seagate CEO William D. Mosley sold $1.59M of STX shares in an open-market transaction filed as an SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely muted given the disclosed 10b5-1 plan.

Evidence & confidence

The filing is a routine insider transaction with a stated pre-arranged 10b5-1 plan; no new operating, financial, or deal catalyst is provided.

Market effects

No sector-wide read-across is implied; this is company-specific insider activity.

Minimal; US-listed single-name disclosure.

Low; no international operational or regulatory developments mentioned.

Counterpoint

A 10b5-1 sale can still coincide with private information or liquidity needs, so traders may treat it as a mild caution signal rather than purely mechanical.

Key entities

  • Seagate Technology Holdings plc

    Subject of the Form 4 insider sale by its CEO.

  • William D. Mosley

    CEO and director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.